Sellas Life Sciences said its Phase 3 trial of galinpepimut-S (GPS) in advanced acute myeloid leukemia met the primary endpoint, reducing the risk of death by 41% versus standard treatment, according to the company. The result positions the cancer vaccine strategy as a late-stage contender in AML, a disease where immunotherapy options remain limited. The announcement is expected to sharpen scrutiny on endpoint definitions, subgroup effects, and the durability of survival benefits as regulators and clinicians weigh where a vaccine approach fits alongside evolving AML standards of care.